|
US 12,084,473 B2 |
|
| β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |
| Jean-Pierre Sommadossi, Boston, MA (US); and Adel Moussa, Burlington, MA (US) |
| Assigned to Atea Pharmaceuticals, Inc., Boston, MA (US) |
| Filed by Atea Pharmaceuticals, Inc., Boston, MA (US) |
| Filed on Jan. 23, 2023, as Appl. No. 18/100,452. |
| Application 18/100,452 is a continuation of application No. 17/306,643, filed on May 3, 2021, abandoned. |
| Application 17/306,643 is a continuation of application No. 17/028,724, filed on Sep. 22, 2020, abandoned. |
| Application 17/028,724 is a continuation of application No. 16/918,914, filed on Jul. 1, 2020, granted, now 10,875,885, issued on Dec. 29, 2020. |
| Application 16/918,914 is a continuation of application No. 16/900,397, filed on Jun. 12, 2020, granted, now 10,870,672, issued on Dec. 22, 2020. |
| Application 16/900,397 is a continuation of application No. 16/278,621, filed on Feb. 18, 2019, granted, now 10,815,266, issued on Oct. 27, 2020. |
| Application 16/278,621 is a continuation of application No. 16/001,549, filed on Jun. 6, 2018, granted, now 10,239,911, issued on Mar. 26, 2019. |
| Application 16/001,549 is a continuation of application No. 15/782,628, filed on Oct. 12, 2017, granted, now 10,000,523, issued on Jun. 19, 2018. |
| Application 15/782,628 is a continuation of application No. 15/063,461, filed on Mar. 7, 2016, granted, now 9,828,410, issued on Nov. 28, 2017. |
| Claims priority of provisional application 62/276,597, filed on Jan. 8, 2016. |
| Claims priority of provisional application 62/253,958, filed on Nov. 11, 2015. |
| Claims priority of provisional application 62/129,319, filed on Mar. 6, 2015. |
| Prior Publication US 2024/0002426 A1, Jan. 4, 2024 |
| This patent is subject to a terminal disclaimer. |
| Int. Cl. C07H 19/207 (2006.01); A61K 31/7076 (2006.01); A61P 31/14 (2006.01); C07H 19/16 (2006.01); C07H 19/20 (2006.01) |
